BRCA1 and ovarian carcinoma: Advances in the understanding of the molecular biology of epithelial ovarian cancer, and the impact of BRCA1 and BRCA2 gene mutations on cellular DNA repair pathways, has led to the development of PARP inhibitors, an exciting new class of targeted therapy.